{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:02:45Z","timestamp":1768777365333,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"DOI":"10.1093\/eurheartj\/ehq522","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T20:40:11Z","timestamp":1297456811000},"page":"1227-1234","source":"Crossref","is-referenced-by-count":115,"title":["Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction"],"prefix":"10.1093","volume":"32","author":[{"given":"Scott D.","family":"Solomon","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung","family":"Hee Shin","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amil","family":"Shah","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hicham","family":"Skali","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Kober","sequence":"additional","affiliation":[{"name":"Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean L.","family":"Rouleau","sequence":"additional","affiliation":[{"name":"University of Montreal, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxzana Y.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Hester","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Boston, MA, USA"},{"name":"University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,2,10]]},"reference":[{"key":"key\n\t\t\t\t20180328180220_EHQ522C1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C4","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C6","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/08037050701717014","article-title":"Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension","volume":"16","author":"Verdecchia","year":"2007","journal-title":"Blood Press"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C9","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C12","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C13","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1161\/01.CIR.0000134791.68010.FA","article-title":"American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C15","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"issue":"6 Suppl","key":"key\n\t\t\t\t20180328180220_EHQ522C16","first-page":"VI40","article-title":"Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Francis","year":"1993","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0735-1097(94)90001-9","article-title":"Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril","volume":"24","author":"Rouleau","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C19","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cardfail.2010.06.417","article-title":"Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacological therapy. Data from the Valsartan Heart Failure trial (Val-HeFT)","volume":"16","author":"Masson","year":"2010","journal-title":"J Card Failure"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(02)02063-6","article-title":"Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study","volume":"40","author":"Wong","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C21","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1210\/endo-87-6-1318","article-title":"The effect of alpha- and beta-adrenergic blocking agents on the renin response to hypoglycemia and epinephrine in dogs","volume":"87","author":"Assaykeen","year":"1970","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C22","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","article-title":"Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C24","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1161\/CIRCULATIONAHA.104.508093","article-title":"Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction","volume":"111","author":"Solomon","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C25","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/eurheartj\/ehq190","article-title":"Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial","volume":"31","author":"Scirica","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C26","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328180220_EHQ522C27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurjhf\/hfq212","article-title":"Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study","volume":"13","author":"Krum","year":"2011","journal-title":"Eur J Heart Failure"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/32\/10\/1227\/17049225\/ehq522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T03:21:27Z","timestamp":1522293687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/32\/10\/1227\/563765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,10]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,2,10]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehq522","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,5]]},"published":{"date-parts":[[2011,2,10]]}}}